Patents by Inventor Damian Brockschnieder
Damian Brockschnieder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230027985Abstract: The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl; R2 is hydrogen or alkyl; A is 5-membered heteroaryl; Z is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; all groups being optionally substituted.Type: ApplicationFiled: November 12, 2020Publication date: January 26, 2023Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc.Inventors: Daniel MEIBOM, Yolanda CANCHO GRANDE, Pierre WASNAIRE, Sarah Anna Liesa JOHANNES, Niels LINDNER, Kristin BEYER, Till FREUDENBERGER, Damian BROCKSCHNIEDER, Ilka MATHAR, Jürgen KLAR, Dmitry ZUBOV, Dzianis MENSHYKAU, Tanja KRAINZ, Eric STEFAN, Bryan MACDONALD, Yi XING, Nadine ELOWE, Guzman SANCHEZ
-
Publication number: 20230027346Abstract: The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.Type: ApplicationFiled: November 12, 2020Publication date: January 26, 2023Applicants: BAYER AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC.Inventors: Daniel MEIBOM, Yolanda CANCHO GRANDE, Pierre WASNAIRE, Sarah Anna Liesa JOHANNES, Kristin BEYER, Till FREUDENBERGER, Damian BROCKSCHNIEDER, Dmitry ZUBOV, Dzianis MENSHYKAU, Tanja KRAINZ, Bryan MACDONALD, Yi XING, Nadine ELOWE, Guzman SANCHEZ
-
Publication number: 20220412975Abstract: Provided herein are assays for the detection and characterization of modulators of ADAMTS-7 and/or ADAMTS-12. Also provided herein are recombinant nucleic acids for the improved expression of functional metalloproteinases ADAMTS-7 and nucleic acids for the improved expression of functional metalloproteinases ADAMTS-12. In addition, provided herein are peptide substrates (e.g. FRET substrates) for use in assays for the detection and characterization of modulators of ADAMTS-7 and/or ADAMTS-12.Type: ApplicationFiled: November 12, 2020Publication date: December 29, 2022Inventors: Dmitry Zubov, Bryan MacDonald, Yi Xing, Nadine Elowe, Damian Brockschnieder
-
Patent number: 11337973Abstract: The invention relates to prolyl endopeptidase (PREP) inhibitors of formula (I) which contain a condensed 2,4-dihydro-3H-1,2,4-triazol-3-one ring system, methods for producing same, the use thereof alone or in combinations for treating and/or preventing diseases, and the use thereof for producing drugs for treating and/or preventing diseases, in particular for treating and/or preventing inflammatory lung diseases (COPD).Type: GrantFiled: October 31, 2018Date of Patent: May 24, 2022Assignees: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Nicole Biber, Damian Brockschnieder, Florian Kölling, Jörg Meding, Hideki Miyatake Ondozabal, Thomas Neubauer, Martina Schäfer, Dmitry Zubov, Carsten Terjung
-
Publication number: 20210220358Abstract: The present invention relates to use 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds for the treatment or prophylaxis of diseases which are associated with nerve fibre sensitization, in particular for treatment and prophylaxis of Chronic Cough (CC), Idiopathic Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Disorder (COPD), and asthma.Type: ApplicationFiled: May 14, 2019Publication date: July 22, 2021Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Christian FRIEDRICH, Isabella GASHAW, Damian BROCKSCHNIEDER, Oliver Martin FISCHER
-
Publication number: 20210147504Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a Brain Natriuretic Peptide (BNP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.Type: ApplicationFiled: April 10, 2019Publication date: May 20, 2021Applicant: Bayer AktiengesellschaftInventors: Damian BROCKSCHNIEDER, Jan TEBBE, Andreas WILMEN, Frank WUNDER
-
Publication number: 20210139555Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Nils), an Atrial Natriuretic Peptide (ANP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.Type: ApplicationFiled: April 10, 2019Publication date: May 13, 2021Applicant: Bayer AktiengesellschaftInventors: Anke MAYER-BARTSCHMID, Damian BROCKSCHNIEDER, Marcel GEERTZ, Simone GREVEN, Lucas Hudson HOFMEISTER, Hannah JÖRISSEN, Christoph MAHLERT, Tobias MARQUARDT, Ilka MATHAR, Thomas MONDRITZKI, Claudia NOACK, Jan TEBBE, Stuart WALSH, Ernst WEBER, Andreas WILMEN, Frank WUNDER
-
Publication number: 20210079056Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a C-Type Natriuretic Peptide (CNP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.Type: ApplicationFiled: April 10, 2019Publication date: March 18, 2021Applicant: Bayer AktiengesellschaftInventors: Damian BROCKSCHNIEDER, Lucas Hudson HOFMEISTER, Claudia NOACK, Jan TEBBE, Stuart WALSH, Andreas WILMEN, Frank WUNDER
-
Publication number: 20200375986Abstract: The invention relates to prolyl endopeptidase (PREP) inhibitors which contain a condensed 2,4-dihydro-3H-1,2,4-triazol-3-one ring system, methods for producing same, the use thereof alone or in combinations for treating and/or preventing diseases, and the use thereof for producing drugs for treating and/or preventing diseases, in particular for treating and/or preventing inflammatory lung diseases (COPD).Type: ApplicationFiled: October 31, 2018Publication date: December 3, 2020Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Nicole BIBER, Damian BROCKSCHNIEDER, Florian KÖLLING, Jörg MEDING, Hideki MIYATAKE ONDOZABAL, Thomas NEUBAUER, Martina SCHÄFER, Dmitry ZUBOV, Carsten TERJUNG
-
Patent number: 10722501Abstract: The present application relates to novel substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones of formula (I), to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of lung inflammation disorders.Type: GrantFiled: May 8, 2017Date of Patent: July 28, 2020Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFTInventors: Nicole Biber, Damian Brockschnieder, Kersten Matthias Gericke, Florian Kölling, Klemens Lustig, Jörg Meding, Heinrich Meier, Thomas Neubauer, Martina Schäfer, Andreas Timmermann, Dmitry Zubov, Carsten Terjung, Niels Lindner, Volker Badock, Dieter Moosmayer, Hideki Miyatake Ondozabal, Stephen Moore, Alexander Schulz
-
Publication number: 20190160048Abstract: The present application relates to novel substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of lung inflammation disorders.Type: ApplicationFiled: May 8, 2017Publication date: May 30, 2019Applicants: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFTInventors: Nicole BIBER, Damian BROCKSCHNIEDER, Kersten Matthias GERICKE, Florian KÖLLING, Klemens LUSTIG, Jörg MEDING, Heinrich MEIER, Thomas NEUBAUER, Martina SCHÄFER, Andreas TIMMERMANN, Dmitry ZUBOV, Carsten TERJUNG, Niels LINDNER, Volker BADOCK, Dieter MOOSMAYER, Hideki MIYATAKE ONDOZABAL, Steven MOORE, Alexander SCHULZ
-
Patent number: 10292970Abstract: The present application relates to novel heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.Type: GrantFiled: November 30, 2015Date of Patent: May 21, 2019Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Alexandros Vakalopoulos, Damian Brockschnieder, Frank Wunder, Johannes-Peter Stasch, Tobias Marquardt, Lisa Dietz, Volkhart Min-Jian Li
-
Patent number: 10214526Abstract: The present application relates to novel substituted pyrazolo[1,5-a]pyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.Type: GrantFiled: February 2, 2016Date of Patent: February 26, 2019Assignee: Bayer Pharma AktiengesellschaftInventors: Alexandros Vakalopoulos, Damian Brockschnieder, Frank Wunder, Johannes-Peter Stasch, Tobias Marquardt, Lisa Dietz, Min Jian Volkhart Li
-
Patent number: 10174021Abstract: The present application relates to novel substituted pyrazolo[1,5-a]pyridines of the formula (I-A) to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.Type: GrantFiled: November 30, 2015Date of Patent: January 8, 2019Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Alexandros Vakalopoulos, Damian Brockschnieder, Frank Wunder, Johannes-Peter Stasch, Tobias Marquardt, Lisa Dietz, Volkhart Min-Jian Li
-
Patent number: 10150773Abstract: The present application relates to novel substituted imidazo[1,2-a]pyrazine carboxamides of general formula (I) to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.Type: GrantFiled: February 2, 2016Date of Patent: December 11, 2018Assignee: Bayer Pharma AktiengesellschaftInventors: Alexandros Vakalopoulos, Damian Brockschnieder, Frank Wunder, Johannes-Peter Stasch, Tobias Marquardt, Lisa Dietz, Min Jian Volkhart Li
-
Publication number: 20180037580Abstract: The present application relates to novel substituted pyrazolo[1,5-a]pyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.Type: ApplicationFiled: February 2, 2016Publication date: February 8, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Alexandros VAKALOPOULOS, Damian BROCKSCHNIEDER, Frank WUNDER, Johannes-Peter STASCH, Tobias MARQUARDT, Lisa DIETZ, Min Jian Volkhart LI
-
Publication number: 20180022751Abstract: The present application relates to novel substituted imidazo[1,2-a]pyrazine carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.Type: ApplicationFiled: February 2, 2016Publication date: January 25, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Alexandros VAKALOPOULOS, Damian BROCKSCHNIEDER, Frank WUNDER, Johannes-Peter STASCH, Tobias MARQUARDT, Lisa DIETZ, Min Jian Volkhart LI
-
Publication number: 20170313700Abstract: The present application relates to novel substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.Type: ApplicationFiled: November 30, 2015Publication date: November 2, 2017Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Alexandros VAKALOPOULOS, Damian BROCKSCHNIEDER, Frank WUNDER, Johannes-Peter STASCH, Tobias MARQUARDT, Lisa DIETZ, Volkhart Min-Jian LI
-
Publication number: 20170304278Abstract: The present application relates to novel heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.Type: ApplicationFiled: November 30, 2015Publication date: October 26, 2017Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Alexandros VAKALOPOULOS, Damian BROCKSCHNIEDER, Frank WUNDER, Johannes-Peter STASCH, Tobias MARQUARDT, Lisa DIETZ, Volkhart Min-Jian LI
-
Publication number: 20170240566Abstract: The present application relates to novel amino-substituted fused pyrimidines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.Type: ApplicationFiled: August 25, 2015Publication date: August 24, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Alexandros VAKALOPOULOS, Gaelle VALOT, Markus FOLLMANN, Damian BROCKSCHNIEDER, Johannes-Peter STASCH, Tobias MARQUARDT, Adrian TERSTEEGEN, Frank WUNDER, Lisa DIETZ, Dieter LANG, Ursula KRENZ